News

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumours and disables immune therapy

The tumour endothelium prevents T-cell homing and hinders tumour immunotherapy, as a research team from the University of Pennsylvania (USA) reports.
The scientists analysed microdissected tumour endothelial cells from human ovarian cancers and found genes that could be linked to absence or presence of tumour-infiltrating lymphocytes. If the gene encoding the endothelin B receptor was overexpressed, tumour-infiltrating lymphocytes were absent and the patients' survival time was rather short. BQ-788, an inhibitor of endothelin B receptor, led to increased T-cell adhesion to human endothelium in vitro. This effect was due to blockage of intercellular adhesion molecule-1 (ICAM-1) or treatment with NO donors.

BQ-788 also neutralised endothelin B receptor in vivo, leading to increased T-cell homing to tumours. It was ICAM-1 which caused the improved T-cell homing and enabled tumour response to usually ineffective immunotherapy in vivo. The molecule did not change the systemic antitumour immune response.

Related antibodies on antibodies-online.com:

Endothelin B Receptor

ICAM-1

T-cells

Endothelial cells

Ovarian carcinoma-associated Antigen

Antibodies for the research area immunology: »Show antibodies

Antibodies for the research area oncology: »Show antibodies

10.03.2008  |  Anna Lena Marwedel      RSS Feed  Research News


RSS Feed  More Headlines: Research News